GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cinclus Pharma Holding AB (OSTO:CINPHA) » Definitions » Notes Receivable

Cinclus Pharma Holding AB (OSTO:CINPHA) Notes Receivable : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cinclus Pharma Holding AB Notes Receivable?

Cinclus Pharma Holding AB's Notes Receivable for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Cinclus Pharma Holding AB Notes Receivable Historical Data

The historical data trend for Cinclus Pharma Holding AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cinclus Pharma Holding AB Notes Receivable Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - -

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cinclus Pharma Holding AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Cinclus Pharma Holding AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Cinclus Pharma Holding AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Cinclus Pharma Holding AB Business Description

Traded in Other Exchanges
N/A
Address
Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a clinical stage pharmaceutical company developing a drug for the treatment of erosive gastroesophageal reflux diseases, and a dual therapy treatment with an antibiotic targeting Helicobacter pylori which is a bacteria that occurs in the gastric and duodenal mucosa. The Company's main target population is patients suffering from severe eGERD, where there is a lack of satisfactory treatment options.

Cinclus Pharma Holding AB Headlines

No Headlines